Free shipping on orders over $150
$49.99
PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It acts on the melanocortin receptors in the central nervous system. Research has focused on its effects on sexual dysfunction and its unique mechanism of action compared to PDE5 inhibitors.
PT-141, also known as Bremelanotide, is a cyclic heptapeptide lactam analog of alpha-melanocyte-stimulating hormone (α-MSH). Originally derived from the superpotent melanocortin agonist Melanotan II, PT-141 has become a subject of significant research interest due to its unique mechanism of action targeting the melanocortin system.
Unlike traditional phosphodiesterase type 5 (PDE5) inhibitors, PT-141 operates through central nervous system pathways, specifically activating melanocortin receptors MC3R and MC4R. This central mechanism of action distinguishes it from peripherally-acting compounds and has opened new avenues of investigation into the neurobiology of physiological responses.
Preclinical studies have demonstrated that PT-141 produces measurable effects through direct activation of neural circuits in the hypothalamus. Research models have shown dose-dependent responses, with investigations focusing on optimal dosing strategies and pharmacokinetic profiles following subcutaneous administration.
Ongoing research continues to explore the broader implications of melanocortin receptor modulation, including potential applications in energy homeostasis, inflammation, and cardiovascular function. The peptide's ability to cross the blood-brain barrier and engage central targets makes it a valuable research tool for studying melanocortin signaling pathways.